Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (June 2023)
20 slides from Inoviq's investor presentation, Jun 29, 2023
Slide 1: SubB2M/CA15-3 clinical validation data
SubB2M/CA15-3 clinical validation data Webinar presentation ASX: IIQ | 29 June 2023
Slide 2: Disclaimer
Disclaimer This presenta tion has been prepa red by INOVIQ Limi ted (“INOVIQ” or the “Company”) Actual resul ts , performance or a chievements could be signi fi cantl y different from those based on i nforma tion a vailable to i tas at the date of this presenta tion. This presenta tion expressed in,
Slide 3: About INOVIQ Ltd
About INOVIQ Ltd INOVIQ’s mission is to develop next-generation precision diagnostics and exosome solutions that transform the diagnosis and treatment of cancer and other diseases to improve patient outcomes and save lives $ Precision Disruptive Deep Compelling Commercial Partnering for focus techno
Slide 4: Company snapshot
Company snapshot INOVIQ snapshot Financial information (ASX:IIQ) • Founded in 2016 as a single-asset diagnostics company focused on earlier cancer Ordinary shares2 92,018,702 detection Listed options2 5,909,965 • Multiple acquisitions and in-licensing to expand technology portfolio • Headquartered i
Slide 5: Products and pipeline | Expanding EXO-NET tools and diagnostics portfolio
Products and pipeline | Expanding EXO-NET tools and diagnostics portfolio ASSAY CLINICAL PRODUCT INDICATION PLATFORM USE RESEARCH DEVELOPMENT DEVELOPMENT MARKET hTERT1 Bl a dder Cancer ICC Adjunct to cytol ogy USA EXO tools/Dx SubB2M Dx SubB2M-BC Brea st Ca ncer Immunoassay Moni toring LDT Dec-23 Su
Slide 6: SubB2M diagnostics
SubB2M diagnostics Improved SubB2M-based cancer diagnostic tests for cancer detection and monitoring neuraminic acid 6
Slide 7: SubB2M/CA15-3 breast cancer test | improved BC monitoring
SubB2M/CA15-3 breast cancer test | improved BC monitoring Clinical-stage and progressing towards market-ready by end 2023 • #1 cancer in women Key milestones Breast cancer • 2.3m new cases of breast cancer worldwide pa 1 • 7.8m 5-year survivors 1 Feasibility Completed • Earlier and more accurate scr
Slide 8: Breast Cancer Test: Study BC04
SubB2M/CA15-3 Breast Cancer Test: Study BC04 Receiver Operating Characteristic Curve Study objectives • To evaluate the clinical performance of the SubB2M/CA15-3 test across all stages of breast cancer compared to healthy controls; and • To compare the performance of the SubB2M/CA15-3 test to a lead
Slide 9: Breast Cancer Test: Study BC04 Study rationale
SubB2M/CA15-3 Breast Cancer Test: Study BC04 Study rationale • Cancer cells have a distinct feature of adding different sugar molecules to the proteins they produce, which sets them apart from normal cells • One such sugar molecule commonly found in cancer cells is Neu5Gc • SubB2M preferentially bin
Slide 10: Breast Cancer Test: Study BC004 SubB2M ELISA Format
SubB2M/CA15-3 Breast Cancer Test: Study BC004 Why should SubB2M improve assay SubB2M ELISA Format performance? Multiple Neu5Gc binding sites on target [CA15.3], therefore, more signal generated which increases the sensitivity of the test. TMB chromogenic signal Step-HRP Cancer cells preferentially u
Slide 11: Breast Cancer Test: Study BC04 Study design
SubB2M/CA15-3 Breast Cancer Test: Study BC04 Study design • Retrospective case : control design (1:1, bio-banked samples) 483 serum samples • Serum sample healthy controls (242) and all stages of breast cancer ( I=75, II=72, 3=72, III=72, IV = 22) • Using SubB2M, we developed a CA15-3 ELISA that onl
Slide 12: Breast Cancer Test: Study BC004 Results
SubB2M/CA15-3 Breast Cancer Test: Study BC004 Receiver Operating Characteristic Curve Results • INOVIQ’s SubB2M/CA15-3 test demonstrated superior diagnostic accuracy compared to a leading CA15-3 IVD in a 483-sample case- control study Table 1: SubB2M/CA15-3 and comparator CA15-3 test performance sum
Slide 13: Breast Cancer Test: Study BC004 Next Steps
SubB2M/CA15-3 Breast Cancer Test: Study BC004 Next Steps • Evaluate the performance of the SubB2M/CA15-3 test for monitoring treatment response and disease recurrence. • Does SubB2M/CA15-3 detect changes in tumor growth earlier than CA15-3 (and other biomarkers) and thus better inform clinical decis
Slide 14: SubB2M/CA125 Ovarian Cancer Test | improved OC monitoring
SubB2M/CA125 Ovarian Cancer Test | improved OC monitoring Progressing towards clinical validation • #8 cancer in women Key milestones Ovarian cancer • 314k new cases of ovarian cancer worldwide pa 1 • 823k 5-year survivors 1 Feasibility Completed • No approved test for early detection of OC in asymp
Slide 15: SubB2M commercialisation
SubB2M commercialisation 15
Slide 16: Market potential | Screening and monitoring tests
Market potential | Screening and monitoring tests Eligible screening Screening market Eligible monitoring Monitoring market Statistics1 population2 size 3 population4 size 5 11.5 1.7 4.0 0.6 Ovarian cancer incidence 28.0 9.1 188.3 6 52,638 60.4 25.1 $1.9b Ovarian 119m USD $18b 367k USD $55m GLOBAL D
Slide 17: SubB2M commercialisation strategy
SubB2M commercialisation strategy Build clinical data Commercialisation Geographic Sell first as an LDT IVD development IVD partnering package paths roll-out via a partner Partner with major Build clinical Market as Lab diagnostic evidence in the Developed Test Commence selling company, Complete IVD
Slide 18: 2023 milestones and catalysts
2023 milestones and catalysts 2H FY2023 1H FY2024 ✓ Results SubB2M/CA15-3 breast cancer study 1 Results SubB2M SPR feasibility study 1 Results SubB2M/CA125 OC study 1 ✓ Results SubB2M/CA15-3 BC clinical validation study 2 (n=483) Progress EXO-NET collaborations/partnering ✓ EXO-NET data presented @I
Slide 19: Summary | Next generation diagnostic solutions advancing towards key milestones
Summary | Next generation diagnostic solutions advancing towards key milestones 1 Innovative 2 Patented 3 Strong 4 Compelling Company Technology Pipeline Results Focused on next-gen diagnostic Proprietary SubB2M & NETs Deep pipeline Data for SubB2M and exosome- and exosome solutions to technologies
Slide 20: Contacts
Contacts Dr Leearne Hinch Dr Gregory Rice Chief Executive Officer Chief Scientific Officer e. lhinch@inoviq.com e. grice@inoviq.com Mark Edwards Chief Financial Officer and Company Secretary e. medwards@inoviq.com INOVIQ Ltd, 23 Normanby Road, Notting Hill, VIC 3168 Australia 20 p. +61 3 9548 7586 |